REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Rating of “Moderate Buy” by Brokerages

by · The Markets Daily

Shares of REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $30.00.

A number of research firms recently commented on RGNX. Stifel Nicolaus boosted their price target on REGENXBIO from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Wall Street Zen raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a report on Monday, November 24th. Royal Bank Of Canada upped their price target on shares of REGENXBIO from $17.00 to $19.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. HC Wainwright reiterated a “buy” rating and set a $34.00 price target on shares of REGENXBIO in a research report on Tuesday, October 7th. Finally, Chardan Capital restated a “buy” rating and set a $52.00 price objective on shares of REGENXBIO in a research report on Thursday, November 20th.

View Our Latest Analysis on RGNX

REGENXBIO Stock Down 2.1%

Shares of NASDAQ:RGNX opened at $14.16 on Monday. The company’s 50 day moving average price is $12.73 and its two-hundred day moving average price is $10.41. REGENXBIO has a 12-month low of $5.03 and a 12-month high of $15.41. The firm has a market cap of $716.78 million, a PE ratio of -4.08 and a beta of 1.14.

REGENXBIO (NASDAQ:RGNX – Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The biotechnology company reported ($1.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.38) by $0.18. The company had revenue of $29.73 million during the quarter, compared to the consensus estimate of $24.41 million. REGENXBIO had a negative net margin of 110.29% and a negative return on equity of 78.29%. On average, research analysts expect that REGENXBIO will post -4.84 EPS for the current year.

Insider Activity at REGENXBIO

In other REGENXBIO news, CEO Curran Simpson sold 20,811 shares of REGENXBIO stock in a transaction dated Thursday, October 9th. The stock was sold at an average price of $12.62, for a total value of $262,634.82. Following the transaction, the chief executive officer owned 216,162 shares in the company, valued at $2,727,964.44. The trade was a 8.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 12.79% of the company’s stock.

Institutional Investors Weigh In On REGENXBIO

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Acadian Asset Management LLC acquired a new stake in REGENXBIO during the 1st quarter worth approximately $1,123,000. Voss Capital LP increased its position in REGENXBIO by 47.4% in the 2nd quarter. Voss Capital LP now owns 575,000 shares of the biotechnology company’s stock valued at $4,721,000 after acquiring an additional 185,000 shares during the period. Assenagon Asset Management S.A. raised its stake in shares of REGENXBIO by 23.2% during the third quarter. Assenagon Asset Management S.A. now owns 705,403 shares of the biotechnology company’s stock valued at $6,807,000 after acquiring an additional 132,942 shares during the last quarter. Squarepoint Ops LLC lifted its holdings in shares of REGENXBIO by 2,049.0% during the second quarter. Squarepoint Ops LLC now owns 219,288 shares of the biotechnology company’s stock worth $1,800,000 after purchasing an additional 209,084 shares during the period. Finally, Invesco Ltd. grew its stake in shares of REGENXBIO by 52.4% in the first quarter. Invesco Ltd. now owns 79,469 shares of the biotechnology company’s stock worth $568,000 after purchasing an additional 27,341 shares during the last quarter. 88.08% of the stock is owned by institutional investors.

REGENXBIO Company Profile

(Get Free Report)

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.

Read More